I don't profess to know how these studies are designed, but if one of the legs of this study is a placebo (no prandial insulin), and the objective is to drive blood sugar lower by increasing basil insulin, without the mealtime bolus, it would seem that to get the patient to a target level, they'll have to increase the basil dose to possibly dangerous levels. If the target is the same for all three legs, I would expect to see a really big spike in hypoglycemic events with the placebo leg, or a really poor showing in reaching the target.

Anyone with deeper knowledge on this have any thoughts on this? All the same, the blind study tells us we won't hear anything and neither will the partner(s) until early next year.